John R. Chiminski Sells 181,458 Shares of Catalent Inc (CTLT) Stock
Catalent Inc (NYSE:CTLT) insider John R. Chiminski sold 181,458 shares of the stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total value of $7,189,365.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Catalent Inc (CTLT) opened at $40.06 on Friday. Catalent Inc has a twelve month low of $25.51 and a twelve month high of $43.39. The company has a current ratio of 2.91, a quick ratio of 2.49 and a debt-to-equity ratio of 2.01. The firm has a market capitalization of $5,320.00, a price-to-earnings ratio of 27.65, a PEG ratio of 2.54 and a beta of 1.41.
Catalent (NYSE:CTLT) last posted its earnings results on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.01. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The company had revenue of $543.90 million during the quarter, compared to the consensus estimate of $490.75 million. During the same quarter last year, the firm earned $0.16 earnings per share. The company’s revenue was up 23.0% on a year-over-year basis. research analysts forecast that Catalent Inc will post 1.46 EPS for the current fiscal year.
CTLT has been the subject of several recent analyst reports. Zacks Investment Research downgraded Catalent from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Bank of America reaffirmed a “buy” rating and set a $40.00 price target (up previously from $38.00) on shares of Catalent in a report on Tuesday, August 29th. William Blair reaffirmed an “ourperform” rating on shares of Catalent in a report on Tuesday, August 29th. ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a report on Thursday, September 7th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $45.00 price target on shares of Catalent in a report on Tuesday, August 29th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Catalent presently has a consensus rating of “Buy” and a consensus price target of $44.44.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Stock Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related stocks with our FREE daily email newsletter.